GHK-Cu Before and After: What Results Actually Look Like at 4, 8, and 12 Weeks

The most rigorous GHK-Cu randomized controlled trial did not run for 12 weeks. It ran for 8. And it found 55.8% reduction in wrinkle volume. The protocol used a lipid-based nano-carrier that delivered GHK-Cu past the skin barrier at concentrations most OTC serums never reach. That study, published in the Journal of Aging Science in 2016, represents the ceiling of what GHK-Cu can do. Most people are nowhere near that ceiling because they are using the wrong delivery system at the wrong concentration for the wrong duration.

GHK-Cu is a tripeptide your body makes naturally as a collagen repair signal. Plasma GHK levels drop more than 60% between your 20s and your 60s, which tracks closely with visible skin aging. Supplementing with GHK-Cu in the right form at the right dose restores a signal your cells are starving for. But restoring a repair signal requires the signal to reach the cells that read it. That is where most protocols fail, before any question of genetics or timing enters the picture.

This article covers what real GHK-Cu before-and-after results look like week by week, what delivery and concentration parameters produced those results, how hair before-and-after compares to skin, and how your collagen genetics shift your personal timeline. For the full breakdown of why GHK-Cu results vary so much between individuals, the GHK-Cu response guide covers the underlying factors in detail.

What GHK-Cu actually does at week 4

At week 4, you will not see measurable wrinkle reduction in most protocols. That is not a failure. It is collagen biology running on schedule.

What is happening internally: GHK-Cu binds copper and enters fibroblasts, activating TGF-beta/Smad2-3 signaling. COL1A1 and COL3A1 gene transcription increases. New collagen precursors form. But collagen fibers require 8-12 weeks to assemble, cross-link, and mature into structural tissue that visibly lifts and smooths skin. The signal arrives in week one. The result shows up in weeks 8 to 12.

What some people notice at week 4: Hydration and texture improvements. GHK-Cu upregulates hyaluronic acid synthase genes alongside collagen genes. Skin that felt rough or dry may feel plumper and smoother. This is real progress. It just is not the wrinkle reduction you are measuring for. If your skin feels different at week 4, the protocol is working. The collagen results follow later.

For most people using OTC serums below 0.05% concentration, week 4 looks like nothing. Because nothing is happening. The dose was never therapeutic to begin with. The concentration problem is separate from the timeline problem, but they compound each other. Most "GHK-Cu didn't work for me at a month" reports come from people who were running a sub-therapeutic concentration protocol and stopped exactly when the collagen work was about to show up on the surface.

What changes at week 8?

Week 8 is where the most impressive published clinical data lives. The Badenhorst et al. 2016 trial in the Journal of Aging Science used 8 weeks as its endpoint, not 12, because the researchers knew that nano-encapsulated delivery would accelerate the results.

"GHK-Cu in a lipid nano-carrier outperformed both Matrixyl 3000 and control serum on all three wrinkle parameters measured by optical profilometry: wrinkle volume reduction (55.8%), wrinkle depth reduction (32.8%), and TIMP-1 upregulation confirming collagen protection."

Badenhorst et al., Journal of Aging Science, 2016

The lipid nano-carrier is the key variable. Standard topical GHK-Cu delivers roughly 1-5% of the applied dose past the stratum corneum into the dermis where fibroblasts live. Lipid encapsulation increases dermal penetration substantially. The 55.8% result is not what you should expect from standard topical application at 0.1%. It is what happens when you solve the penetration problem that limits every topical peptide.

For standard topical application at 0.1% concentration, week 8 is where early results appear in people with responsive collagen genetics. Fine lines in high-movement areas (around the eyes, lip line, brow) soften first. These areas have less structural depth, so early collagen gains produce visible surface differences before deeper wrinkles shift.

Hair results at week 8

Hair results from GHK-Cu appear faster than skin results. GHK-Cu activates follicle stem cells and promotes angiogenesis around the follicle base, a different mechanism from its collagen effects in skin. People using GHK-Cu for early androgenetic alopecia or diffuse thinning typically report visible changes in shedding rate and hair density at 8-10 weeks, several weeks ahead of wrinkle changes.

The mechanism is distinct from topical minoxidil or finasteride. GHK-Cu does not block DHT. It improves follicle environment by promoting blood flow and upregulating growth factors locally. This makes it a reasonable adjunct rather than a direct alternative. It also means the "before and after" markers for hair (shedding frequency, density appearance) are different from the markers for skin (wrinkle depth, firmness), and the timeline for each is different.

What the 12-week trials actually show

The most widely cited 12-week clinical data on GHK-Cu comes from Leyden et al., published in Dermatologic Surgery in 2005. The trial enrolled 67-71 women with photoaged facial skin and measured outcomes via dermal ultrasound over 12 weeks. Results included significant increases in skin density and thickness, reduced fine line depth, and reduced skin laxity. The comparison findings are the most useful benchmark:

That 70% response rate is more useful for real-world expectation-setting than any average. It tells you that roughly 30% of people on a well-designed GHK-Cu protocol at 12 weeks will see no measurable response by that point. Some of those people are slow-repair genetic variants who need 16 weeks. Others are using sub-therapeutic products. Others have inflammatory baseline conditions that compete with the collagen signal. The non-response at 12 weeks is not random. It is almost always traceable to one of these three factors.

The 12-week clinical framework exists because collagen remodeling research needs this window to capture the full induction and maturation cycle. A 2009 review of topical peptides by Gorouhi and Maibach in the International Journal of Cosmetic Science established that collagen-stimulating compounds require 12-week minimum trials because earlier endpoints measure the induction phase rather than the structural outcome. The Leyden data confirms this in the GHK-Cu context specifically.

Why most before-and-after photos tell you nothing

Before-and-after photos shared by brands and influencers almost never disclose: the GHK-Cu concentration in the product, whether nano-encapsulation or other delivery enhancement was used, the age of the subject and their baseline collagen status, the standardization of lighting and camera angle, or the total protocol length.

Clinical trials control for all of these. Consumer photos control for none. The 55.8% wrinkle volume reduction from Badenhorst 2016 was measured by optical profilometry under controlled conditions, comparing standardized skin scans before and after treatment. The before-and-after photo on a product page is often better-rested skin, different lighting, post-hydration glow, or improved makeup removal technique on the "after" shot.

The most honest before-and-after comparison you can run is a standardized skin scan at week 0 and week 12, taken by a dermatologist or aesthetician using consistent equipment. If you are using a consumer protocol, photographs taken in identical conditions (same lighting, same time of day, same camera distance) at least remove the lighting variable.

Injectable GHK-Cu: the 2026 regulatory update

Injectable GHK-Cu was placed on the FDA's Category 2 "do not compound" list in September 2023. On April 22, 2026, the FDA removed injectable GHK-Cu from Category 2 as part of a broader removal of 12 peptides. This removal happened because nominators withdrew their Category 2 nominations, not because the FDA found injectable GHK-Cu safe and effective for compounding. The status is transitional.

A formal PCAC review is scheduled for February 2027. Until then, compounding pharmacies can technically prepare injectable GHK-Cu under 503A rules with a patient-specific prescription, but full eligibility has not been established. If you are pursuing injectable GHK-Cu, verify your provider's compliance status and whether they are operating under sterile compounding standards. Topical compounded GHK-Cu at 0.1% remains fully available through physician-prescribed compounding pharmacies. See the GHK-Cu peptide profile for current sourcing and legal status.

How your collagen genes determine your personal before-and-after window

The 70% response rate from Leyden 2005 means 30% of people on a 12-week protocol will not show measurable results at that checkpoint. That 30% is not random. COL1A1 and TGFB1 variants explain a significant portion of the variance between people running identical protocols.

COL1A1 encodes type-I collagen. Promoter variants in COL1A1 affect how aggressively fibroblasts transcribe new collagen when they receive the GHK-Cu signal. Slow-repair variants produce less collagen per signal cycle. The signal still works. The response just arrives later. For these individuals, a 12-week measurement endpoint produces a false negative. The protocol needs 16 weeks before the collagen output is sufficient to show up in surface wrinkle measurements.

TGFB1 encodes TGF-beta-1, GHK-Cu's primary downstream effector in the collagen pathway. TGFB1 variants determine how strongly your cells amplify the collagen signal once it arrives. Low-amplification genotypes benefit most from delivery enhancement (microneedling, nano-encapsulation) rather than just extending the protocol length. The DNA-first peptide protocol framework walks through how to use your specific variant profile to choose the right delivery approach before you start.

Your age modifies all three genetic factors in your favor if you are over 45. Plasma GHK drops more than 60% between your 20s and 60. The deeper your GHK deficit, the faster your cells respond when you supply it at therapeutic concentration. Clinical trials consistently show stronger absolute results in the 45-65 age range compared to younger participants, regardless of genetic variant status. If you are older and have slow-repair variants, the genetic disadvantage is partially offset by the larger deficit your collagen system has to fill.

If you have 23andMe or AncestryDNA raw data, your COL1A1, TGFB1, and MC1R variants are typically callable from standard consumer SNP arrays. Knowing your variant profile before you start saves weeks of uncertainty about whether the protocol is working or whether your timeline is simply longer than average. The full GHK-Cu evidence base covers what to expect once your protocol is correctly calibrated.